{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:51:32Z","timestamp":1781772692298,"version":"3.54.5"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"crossref","award":["File No. SRG2022-00042-ICMS and MYRG-GRG2024-00245-ICMS-UMDF"],"award-info":[{"award-number":["File No. SRG2022-00042-ICMS and MYRG-GRG2024-00245-ICMS-UMDF"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Science and Technology Development Fund, Macau SAR","award":["FDCT, File No. 0048\/2024\/ITP2, 0007\/2022\/AKP, 005\/2023\/SKL, 0001\/2025\/AKP, 0002\/2025\/NRP, and 0008\/2025\/EQP"],"award-info":[{"award-number":["FDCT, File No. 0048\/2024\/ITP2, 0007\/2022\/AKP, 005\/2023\/SKL, 0001\/2025\/AKP, 0002\/2025\/NRP, and 0008\/2025\/EQP"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02990-1","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:04:08Z","timestamp":1780725848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding TNF receptor superfamily control of CD4+Foxp3+ Regulatory T cell-mediated tolerance: implications for the treatment of graft\u2011versus\u2011host disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Chon-Kit","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"9","key":"2990_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/annonc\/mdm064","volume":"18","author":"M Devetten","year":"2007","unstructured":"Devetten M, Armitage JO. Hematopoietic cell transplantation: progress and obstacles. Ann Oncol. 2007;18(9):1450\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdm064.","journal-title":"Ann Oncol"},{"issue":"3","key":"2990_CR2","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/s2352-3026(","volume":"2","author":"A Gratwohl","year":"2015","unstructured":"Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2(3):e91\u2013100. https:\/\/doi.org\/10.1016\/s2352-3026(. 15)00028\u2009\u2013\u20099.","journal-title":"Lancet Haematol"},{"issue":"12","key":"2990_CR3","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371\u201383. https:\/\/doi.org\/10.1182\/blood-2008-03-077974.","journal-title":"Blood"},{"issue":"3","key":"2990_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2003-02-0342","volume":"103","author":"HJ Kolb","year":"2004","unstructured":"Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767\u201376. https:\/\/doi.org\/10.1182\/blood-2003-02-0342.","journal-title":"Blood"},{"issue":"22","key":"2990_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017;377(22):2167\u201379. https:\/\/doi.org\/10.1056\/NEJMra1609337.","journal-title":"N Engl J Med"},{"issue":"26","key":"2990_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377(26):2565\u201379. https:\/\/doi.org\/10.1056\/NEJMra1703472.","journal-title":"N Engl J Med"},{"issue":"3","key":"2990_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/blood-2014-01-514786","volume":"124","author":"SG Holtan","year":"2014","unstructured":"Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood. 2014;124(3):363\u201373. https:\/\/doi.org\/10.1182\/blood-2014-01-514786.","journal-title":"Blood"},{"issue":"20","key":"2990_CR8","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","volume":"5","author":"Z DeFilipp","year":"2021","unstructured":"DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5(20):4278\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2021004941.","journal-title":"Blood Adv"},{"issue":"22","key":"2990_CR9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood.2021012431","volume":"138","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Teshima T. Nonclassical manifestations of acute GVHD. Blood. 2021;138(22):2165\u201372. https:\/\/doi.org\/10.1182\/blood.2021012431.","journal-title":"Blood"},{"issue":"3","key":"2990_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2503189","volume":"393","author":"DJ Curtis","year":"2025","unstructured":"Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. N Engl J Med. 2025;393(3):243\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2503189.","journal-title":"N Engl J Med"},{"issue":"2","key":"2990_CR11","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/s2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11(2):e147\u201359. https:\/\/doi.org\/10.1016\/s2352-3026(23)00342-3.","journal-title":"Lancet Haematol"},{"issue":"9674","key":"2990_CR12","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/s0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(09)60237-3.","journal-title":"Lancet"},{"issue":"13","key":"2990_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood.2023021815","volume":"143","author":"A Mathioudaki","year":"2024","unstructured":"Mathioudaki A, Wang X, Sedloev D, Huth R, Kamal A, Hundemer M, et al. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood. 2024;143(13):1269\u201381. https:\/\/doi.org\/10.1182\/blood.2023021815.","journal-title":"Blood"},{"issue":"8","key":"2990_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41409-017-0078-0","volume":"53","author":"M van den Brink","year":"2018","unstructured":"van den Brink M, Uhrberg M, Jahn L, DiPersio JF, Pulsipher MA. Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance. Bone Marrow Transpl. 2018;53(8):949\u201359. https:\/\/doi.org\/10.1038\/s41409-017-0078-0.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2990_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin C, Vo LT, Bluestone JA. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158\u201372. https:\/\/doi.org\/10.1038\/s41577-019-0232-6.","journal-title":"Nat Rev Immunol"},{"issue":"29","key":"2990_CR16","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.1073\/pnas.0711106105","volume":"105","author":"Y Onishi","year":"2008","unstructured":"Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3\u2009+\u2009natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113\u20138. https:\/\/doi.org\/10.1073\/pnas.0711106105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2990_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","volume":"36","author":"LS Walker","year":"2015","unstructured":"Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015;36(2):63\u201370. https:\/\/doi.org\/10.1016\/j.it.2014.12.001.","journal-title":"Trends Immunol"},{"issue":"9","key":"2990_CR18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","volume":"20","author":"J Wang","year":"2023","unstructured":"Wang J, Zhao X, Wan YY. Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology. Cell Mol Immunol. 2023;20(9):1002\u201322. https:\/\/doi.org\/10.1038\/s41423-023-01036-7.","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"2990_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ni.2406","volume":"13","author":"J Banchereau","year":"2012","unstructured":"Banchereau J, Pascual V, O\u2019Garra A, From. IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13(10):925\u201331. https:\/\/doi.org\/10.1038\/ni.2406.","journal-title":"Nat Immunol"},{"key":"2990_CR20","doi-asserted-by":"publisher","first-page":"1166135","DOI":"10.3389\/fimmu.2023.1166135","volume":"14","author":"JA Bluestone","year":"2023","unstructured":"Bluestone JA, McKenzie BS, Beilke J, Ramsdell F. Opportunities for Treg cell therapy for the treatment of human disease. Front Immunol. 2023;14:1166135. https:\/\/doi.org\/10.3389\/fimmu.2023.1166135.","journal-title":"Front Immunol"},{"issue":"1","key":"2990_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nm1688","volume":"14","author":"O Joffre","year":"2008","unstructured":"Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P, et al. Prevention of acute and chronic allograft rejection with CD4\u2009+\u2009CD25+Foxp3\u2009+\u2009regulatory T lymphocytes. Nat Med. 2008;14(1):88\u201392. https:\/\/doi.org\/10.1038\/nm1688.","journal-title":"Nat Med"},{"issue":"18","key":"2990_CR22","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/blood.2024026446","volume":"145","author":"EH Meyer","year":"2025","unstructured":"Meyer EH, Pavlova A, Villar-Prados A, Bader C, Xie B, Muffly L, et al. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood. 2025;145(18):2012\u201324. https:\/\/doi.org\/10.1182\/blood.2024026446.","journal-title":"Blood"},{"issue":"3","key":"2990_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41409-024-02199-1","volume":"59","author":"A Velardi","year":"2024","unstructured":"Velardi A, Mancusi A, Ruggeri L, Pierini A. How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia. Bone Marrow Transpl. 2024;59(3):301\u20135. https:\/\/doi.org\/10.1038\/s41409-024-02199-1.","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"2990_CR24","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood.2025028418","volume":"146","author":"D McManus","year":"2025","unstructured":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, et al. Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT. Blood. 2025;146(22):2710\u201327. https:\/\/doi.org\/10.1182\/blood.2025028418.","journal-title":"Blood"},{"key":"2990_CR25","doi-asserted-by":"publisher","first-page":"1604483","DOI":"10.3389\/fimmu.2025.1604483","volume":"16","author":"J Stoops","year":"2025","unstructured":"Stoops J, Morton T, Powell J, Pace AL, Bluestone JA. Treg cell therapy manufacturability: current state of the art, challenges and new opportunities. Front Immunol. 2025;16:1604483. https:\/\/doi.org\/10.3389\/fimmu.2025.1604483.","journal-title":"Front Immunol"},{"issue":"669","key":"2990_CR26","doi-asserted-by":"publisher","first-page":"eabo2628","DOI":"10.1126\/scitranslmed.abo2628","volume":"14","author":"Q Tang","year":"2022","unstructured":"Tang Q, Leung J, Peng Y, Sanchez-Fueyo A, Lozano JJ, Lam A, et al. Selective decrease of donor-reactive T(regs) after liver transplantation limits T(reg) therapy for promoting allograft tolerance in humans. Sci Transl Med. 2022;14(669):eabo2628. https:\/\/doi.org\/10.1126\/scitranslmed.abo2628.","journal-title":"Sci Transl Med"},{"key":"2990_CR27","doi-asserted-by":"publisher","unstructured":"Efe O, Gassen RB, Morena L, Ganchiku Y, Al Jurdi A, Lape IT, et al. A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models. J Clin Invest. 2024;134(5). https:\/\/doi.org\/10.1172\/jci173107.","DOI":"10.1172\/jci173107"},{"issue":"21","key":"2990_CR28","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","volume":"6","author":"JS Whangbo","year":"2022","unstructured":"Whangbo JS, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Rai SC, et al. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022;6(21):5786\u201396. https:\/\/doi.org\/10.1182\/bloodadvances.2021006625.","journal-title":"Blood Adv"},{"issue":"5","key":"2990_CR29","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1182\/bloodadvances.2023011625","volume":"8","author":"CS Bader","year":"2024","unstructured":"Bader CS, Pavlova A, Lowsky R, Muffly LS, Shiraz P, Arai S, et al. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD. Blood Adv. 2024;8(5):1105\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2023011625.","journal-title":"Blood Adv"},{"key":"2990_CR30","doi-asserted-by":"publisher","first-page":"104044","DOI":"10.1016\/j.cellimm.2020.104044","volume":"348","author":"A Cort\u00e9s-Hern\u00e1ndez","year":"2020","unstructured":"Cort\u00e9s-Hern\u00e1ndez A, Alvarez-Salazar E, Arteaga-Cruz S, Alberu-G\u00f3mez J, Soldevila G. Ex vivo expansion of regulatory T cells from long-term Belatacept-treated kidney transplant patients restores their phenotype and suppressive function but not their FOXP3 TSDR demethylation status. Cell Immunol. 2020;348:104044. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104044.","journal-title":"Cell Immunol"},{"issue":"1","key":"2990_CR31","doi-asserted-by":"publisher","first-page":"e1373236","DOI":"10.1080\/2162402x.2017.1373236","volume":"7","author":"JL Cohen","year":"2017","unstructured":"Cohen JL, Wood KJ. TNFR2: The new Treg switch? Oncoimmunology. 2017;7(1):e1373236. https:\/\/doi.org\/10.1080\/2162402x.2017.1373236.","journal-title":"Oncoimmunology"},{"issue":"Suppl 3","key":"2990_CR32","doi-asserted-by":"publisher","first-page":"e000738","DOI":"10.1136\/esmoopen-2020-000738","volume":"4","author":"G Buzzatti","year":"2020","unstructured":"Buzzatti G, Dellepiane C, Del Mastro L. New emerging targets in cancer immunotherapy: the role of GITR. ESMO Open. 2020;4(Suppl 3):e000738. https:\/\/doi.org\/10.1136\/esmoopen-2020-000738.","journal-title":"ESMO Open"},{"issue":"3","key":"2990_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","volume":"10","author":"Y Fu","year":"2020","unstructured":"Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020;10(3):414\u201333. https:\/\/doi.org\/10.1016\/j.apsb.2019.08.010.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"2990_CR34","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1182\/blood-2016-04-711275","volume":"128","author":"A Pierini","year":"2016","unstructured":"Pierini A, Strober W, Moffett C, Baker J, Nishikii H, Alvarez M, et al. TNF-\u03b1 priming enhances CD4\u2009+\u2009FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood. 2016;128(6):866\u201371. https:\/\/doi.org\/10.1182\/blood-2016-04-711275.","journal-title":"Blood"},{"issue":"24","key":"2990_CR35","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood-2016-06-723783","volume":"128","author":"H Nishikii","year":"2016","unstructured":"Nishikii H, Kim BS, Yokoyama Y, Chen Y, Baker J, Pierini A, et al. DR3 signaling modulates the function of Foxp3\u2009+\u2009regulatory T cells and the severity of acute graft-versus-host disease. Blood. 2016;128(24):2846\u201358. https:\/\/doi.org\/10.1182\/blood-2016-06-723783.","journal-title":"Blood"},{"key":"2990_CR36","doi-asserted-by":"publisher","unstructured":"Ma X, Cao L, Raneri M, Wang H, Cao Q, Zhao Y, et al. Human HLA-DR+CD27\u2009+\u2009regulatory T cells show enhanced antigen-specific suppressive function. JCI Insight. 2023;8(23). https:\/\/doi.org\/10.1172\/jci.insight.162978.","DOI":"10.1172\/jci.insight.162978"},{"issue":"4","key":"2990_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-3083.2007.01994.x","volume":"66","author":"P Zhang","year":"2007","unstructured":"Zhang P, Gao F, Wang Q, Wang X, Zhu F, Ma C, et al. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scand J Immunol. 2007;66(4):435\u201340. https:\/\/doi.org\/10.1111\/j.1365-3083.2007.01994.x.","journal-title":"Scand J Immunol"},{"issue":"12","key":"2990_CR38","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.4049\/jimmunol.1201090","volume":"189","author":"A Schoenbrunn","year":"2012","unstructured":"Schoenbrunn A, Frentsch M, Kohler S, Keye J, Dooms H, Moewes B, et al. A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3\u2009+\u2009Treg. J Immunol. 2012;189(12):5985\u201394. https:\/\/doi.org\/10.4049\/jimmunol.1201090.","journal-title":"J Immunol"},{"issue":"1","key":"2990_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41419-018-1266-6","volume":"10","author":"S Yang","year":"2019","unstructured":"Yang S, Xie C, Chen Y, Wang J, Chen X, Lu Z, et al. Differential roles of TNF\u03b1-TNFR1 and TNF\u03b1-TNFR2 in the differentiation and function of CD4(+)Foxp3(+) induced Treg cells in vitro and in vivo periphery in autoimmune diseases. Cell Death Dis. 2019;10(1):27. https:\/\/doi.org\/10.1038\/s41419-018-1266-6.","journal-title":"Cell Death Dis"},{"issue":"23","key":"2990_CR40","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1016\/j.febslet.2011.04.025","volume":"585","author":"X Chen","year":"2011","unstructured":"Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 2011;585(23):3611\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2011.04.025.","journal-title":"FEBS Lett"},{"issue":"5","key":"2990_CR41","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1189\/jlb.3A0915-399R","volume":"99","author":"V Pucino","year":"2016","unstructured":"Pucino V, Lucherini OM, Perna F, Obici L, Merlini G, Cattalini M, et al. Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4\u2009+\u2009T cell functions in TNFR1-associated periodic syndrome. J Leukoc Biol. 2016;99(5):761\u20139. https:\/\/doi.org\/10.1189\/jlb.3A0915-399R.","journal-title":"J Leukoc Biol"},{"key":"2990_CR42","doi-asserted-by":"publisher","first-page":"1387975","DOI":"10.3389\/fimmu.2024.1387975","volume":"15","author":"Y Zong","year":"2024","unstructured":"Zong Y, Deng K, Chong WP. Regulation of Treg cells by cytokine signaling and co-stimulatory molecules. Front Immunol. 2024;15:1387975. https:\/\/doi.org\/10.3389\/fimmu.2024.1387975.","journal-title":"Front Immunol"},{"issue":"1","key":"2990_CR43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4049\/jimmunol.168.1.483","volume":"168","author":"CM McKee","year":"2002","unstructured":"McKee CM, Defina R, He H, Haley KJ, Stone JR, Perkins DL. Prolonged allograft survival in TNF receptor 1-deficient recipients is due to immunoregulatory effects, not to inhibition of direct antigraft cytotoxicity. J Immunol. 2002;168(1):483\u20139. https:\/\/doi.org\/10.4049\/jimmunol.168.1.483.","journal-title":"J Immunol"},{"issue":"12","key":"2990_CR44","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1073\/pnas.0600499103","volume":"103","author":"Y Tian","year":"2006","unstructured":"Tian Y, Jochum W, Georgiev P, Moritz W, Graf R, Clavien PA. Kupffer cell-dependent TNF-alpha signaling mediates injury in the arterialized small-for-size liver transplantation in the mouse. Proc Natl Acad Sci U S A. 2006;103(12):4598\u2013603. https:\/\/doi.org\/10.1073\/pnas.0600499103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2990_CR45","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.healun.2024.11.020","volume":"44","author":"L Levy","year":"2025","unstructured":"Levy L, Moshkelgosha S, Huszti E, Wang S, Hunter S, Zhang CYK, et al. Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation. J Heart Lung Transpl. 2025;44(4):634\u201342. https:\/\/doi.org\/10.1016\/j.healun.2024.11.020.","journal-title":"J Heart Lung Transpl"},{"issue":"2","key":"2990_CR46","doi-asserted-by":"publisher","first-page":"e1871","DOI":"10.1016\/j.jtct.2023.11.016","volume":"30","author":"A Pedraza","year":"2024","unstructured":"Pedraza A, Salas MQ, Rodr\u00edguez-Lobato LG, Escribano-Serrat S, Su\u00e1rez-Lledo M, Mart\u00ednez-Cebrian N, et al. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation. Transpl Cell Ther. 2024;30(2):e1871\u201312. https:\/\/doi.org\/10.1016\/j.jtct.2023.11.016.","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"2990_CR47","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.healun.2021.05.017","volume":"40","author":"L Levy","year":"2021","unstructured":"Levy L, Huszti E, Ahmed M, Ghany R, Hunter S, Moshkelgosha S, et al. Bronchoalveolar lavage cytokine-based risk stratification of minimal acute rejection in clinically stable lung transplant recipients. J Heart Lung Transpl. 2021;40(12):1540\u20139. https:\/\/doi.org\/10.1016\/j.healun.2021.05.017.","journal-title":"J Heart Lung Transpl"},{"issue":"16","key":"2990_CR48","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2012-01-403063","volume":"119","author":"JE Levine","year":"2012","unstructured":"Levine JE, Logan BR, Wu J, Alousi AM, Bola\u00f1os-Meade J, Ferrara JL, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012;119(16):3854\u201360. https:\/\/doi.org\/10.1182\/blood-2012-01-403063.","journal-title":"Blood"},{"issue":"9","key":"2990_CR49","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/bmt.2017.121","volume":"52","author":"E Mir","year":"2017","unstructured":"Mir E, Palomo M, Rovira M, Pereira A, Escolar G, Penack O, et al. Endothelial damage is aggravated in acute GvHD and could predict its development. Bone Marrow Transpl. 2017;52(9):1317\u201325. https:\/\/doi.org\/10.1038\/bmt.2017.121.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2990_CR50","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.bbmt.2012.03.013","volume":"18","author":"SW Choi","year":"2012","unstructured":"Choi SW, Stiff P, Cooke K, Ferrara JL, Braun T, Kitko C, et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transpl. 2012;18(10):1525\u201332. https:\/\/doi.org\/10.1016\/j.bbmt.2012.03.013.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2990_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fcell.2019.00091","volume":"7","author":"H Wajant","year":"2019","unstructured":"Wajant H, Siegmund D. TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages. Front Cell Dev Biol. 2019;7:91. https:\/\/doi.org\/10.3389\/fcell.2019.00091.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2990_CR52","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/art.38755","volume":"66","author":"FE McCann","year":"2014","unstructured":"McCann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, et al. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 2014;66(10):2728\u201338. https:\/\/doi.org\/10.1002\/art.38755.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2990_CR53","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2567.2011.03460.x","volume":"133","author":"X Chen","year":"2011","unstructured":"Chen X, Oppenheim JJ. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology. 2011;133(4):426\u201333. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03460.x.","journal-title":"Immunology"},{"issue":"1","key":"2990_CR54","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41419-025-07609-w","volume":"16","author":"A Albini","year":"2025","unstructured":"Albini A, Di Paola L, Mei G, Baci D, Fusco N, Corso G, et al. Inflammation and cancer cell survival: TRAF2 as a key player. Cell Death Dis. 2025;16(1):292. https:\/\/doi.org\/10.1038\/s41419-025-07609-w.","journal-title":"Cell Death Dis"},{"issue":"10","key":"2990_CR55","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.4049\/jimmunol.180.10.6467","volume":"180","author":"X Chen","year":"2008","unstructured":"Chen X, Subleski JJ, Kopf H, Howard OM, M\u00e4nnel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4\u2009+\u2009CD25+FoxP3\u2009+\u2009T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180(10):6467\u201371. https:\/\/doi.org\/10.4049\/jimmunol.180.10.6467.","journal-title":"J Immunol"},{"key":"2990_CR56","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3389\/fimmu.2018.00573","volume":"9","author":"PCM Urbano","year":"2018","unstructured":"Urbano PCM, Koenen H, Joosten I, He X. An Autocrine TNF\u03b1-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability In Vitro. Front Immunol. 2018;9:573. https:\/\/doi.org\/10.3389\/fimmu.2018.00573.","journal-title":"Front Immunol"},{"issue":"9","key":"2990_CR57","doi-asserted-by":"publisher","first-page":"114724","DOI":"10.1016\/j.celrep.2024.114724","volume":"43","author":"JGC Peeters","year":"2024","unstructured":"Peeters JGC, Silveria S, Ozdemir M, Ramachandran S, DuPage M. Hyperactivating EZH2 to augment H3K27me3 levels in regulatory T cells enhances immune suppression by driving early effector differentiation. Cell Rep. 2024;43(9):114724. https:\/\/doi.org\/10.1016\/j.celrep.2024.114724.","journal-title":"Cell Rep"},{"issue":"7","key":"2990_CR58","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/eji.201041205","volume":"41","author":"R Hamano","year":"2011","unstructured":"Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol. 2011;41(7):2010\u201320. https:\/\/doi.org\/10.1002\/eji.201041205.","journal-title":"Eur J Immunol"},{"issue":"1","key":"2990_CR59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2013.09.008","volume":"65","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Hu Y, Howard OM, Oppenheim JJ, Chen X. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo. Cytokine. 2014;65(1):56\u201364. https:\/\/doi.org\/10.1016\/j.cyto.2013.09.008.","journal-title":"Cytokine"},{"issue":"9","key":"2990_CR60","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/eji.70062","volume":"55","author":"G Tucci","year":"2025","unstructured":"Tucci G, Pacella I, Pinzon Grimaldos A, Rossi A, Cammarata I, Zagaglioni M, et al. TNF Production or TNFR2 Expression Characterize Distinct States of Regulatory T Cells that Cooperate in Treg Expansion in Cancer and Chronic Inflammation. Eur J Immunol. 2025;55(9):e70062. https:\/\/doi.org\/10.1002\/eji.70062.","journal-title":"Eur J Immunol"},{"issue":"4","key":"2990_CR61","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/eji.200940022","volume":"40","author":"X Chen","year":"2010","unstructured":"Chen X, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, Oppenheim JJ. Co-expression of TNFR2 and CD25 identifies more of the functional CD4\u2009+\u2009FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol. 2010;40(4):1099\u2013106. https:\/\/doi.org\/10.1002\/eji.200940022.","journal-title":"Eur J Immunol"},{"issue":"4","key":"2990_CR62","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1172\/jci6896","volume":"104","author":"GR Hill","year":"1999","unstructured":"Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999;104(4):459\u201367. https:\/\/doi.org\/10.1172\/jci6896.","journal-title":"J Clin Invest"},{"key":"2990_CR63","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3389\/fimmu.2017.01471","volume":"8","author":"T Schmid","year":"2017","unstructured":"Schmid T, Falter L, Weber S, M\u00fcller N, Molitor K, Zeller D, et al. Chronic Inflammation Increases the Sensitivity of Mouse Treg for TNFR2 Costimulation. Front Immunol. 2017;8:1471. https:\/\/doi.org\/10.3389\/fimmu.2017.01471.","journal-title":"Front Immunol"},{"key":"2990_CR64","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3389\/fphar.2019.01490","volume":"10","author":"T Padutsch","year":"2019","unstructured":"Padutsch T, Sendetski M, Huber C, Peters N, Pfizenmaier K, Bethea JR, et al. Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein. Front Pharmacol. 2019;10:1490. https:\/\/doi.org\/10.3389\/fphar.2019.01490.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2990_CR65","doi-asserted-by":"publisher","first-page":"e0156311","DOI":"10.1371\/journal.pone.0156311","volume":"11","author":"X He","year":"2016","unstructured":"He X, Landman S, Bauland SC, van den Dolder J, Koenen HJ, Joosten I. A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells. PLoS ONE. 2016;11(5):e0156311. https:\/\/doi.org\/10.1371\/journal.pone.0156311.","journal-title":"PLoS ONE"},{"key":"2990_CR66","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/srep03153","volume":"3","author":"Y Okubo","year":"2013","unstructured":"Okubo Y, Mera T, Wang L, Faustman DL. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep. 2013;3:3153. https:\/\/doi.org\/10.1038\/srep03153.","journal-title":"Sci Rep"},{"issue":"2","key":"2990_CR67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imm.12241","volume":"142","author":"Y Hu","year":"2014","unstructured":"Hu Y, Xiao H, Shi T, Oppenheim JJ, Chen X. Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4(+) Foxp3(+) regulatory T cells. Immunology. 2014;142(2):193\u2013201. https:\/\/doi.org\/10.1111\/imm.12241.","journal-title":"Immunology"},{"issue":"42","key":"2990_CR68","doi-asserted-by":"publisher","first-page":"68278","DOI":"10.18632\/oncotarget.11943","volume":"7","author":"GS Williams","year":"2016","unstructured":"Williams GS, Mistry B, Guillard S, Ulrichsen JC, Sandercock AM, Wang J, et al. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget. 2016;7(42):68278\u201391. https:\/\/doi.org\/10.18632\/oncotarget.11943.","journal-title":"Oncotarget"},{"issue":"1","key":"2990_CR69","doi-asserted-by":"publisher","first-page":"12079","DOI":"10.1038\/s41598-018-30621-4","volume":"8","author":"J Wang","year":"2018","unstructured":"Wang J, Ferreira R, Lu W, Farrow S, Downes K, Jermutus L, et al. TNFR2 ligation in human T regulatory cells enhances IL2-induced cell proliferation through the non-canonical NF-\u03baB pathway. Sci Rep. 2018;8(1):12079. https:\/\/doi.org\/10.1038\/s41598-018-30621-4.","journal-title":"Sci Rep"},{"key":"2990_CR70","doi-asserted-by":"publisher","first-page":"149498","DOI":"10.1016\/j.bbrc.2024.149498","volume":"697","author":"M Inoue","year":"2024","unstructured":"Inoue M, Tsuji Y, Kashiwada A, Yokoyama A, Iwata A, Abe Y, et al. An immunocytokine consisting of a TNFR2 agonist and TNFR2 scFv enhances the expansion of regulatory T cells through TNFR2 clustering. Biochem Biophys Res Commun. 2024;697:149498. https:\/\/doi.org\/10.1016\/j.bbrc.2024.149498.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2990_CR71","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1038\/s41598-023-40925-9","volume":"13","author":"M Inoue","year":"2023","unstructured":"Inoue M, Tsuji Y, Ueno R, Miyamoto D, Tanaka K, Moriyasu Y, et al. Bivalent structure of a TNFR2-selective and agonistic TNF-alpha mutein Fc-fusion protein enhances the expansion activity of regulatory T cells. Sci Rep. 2023;13(1):13762. https:\/\/doi.org\/10.1038\/s41598-023-40925-9.","journal-title":"Sci Rep"},{"issue":"9","key":"2990_CR72","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1084\/jem.20151563","volume":"213","author":"M Chopra","year":"2016","unstructured":"Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, et al. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med. 2016;213(9):1881\u2013900. https:\/\/doi.org\/10.1084\/jem.20151563.","journal-title":"J Exp Med"},{"issue":"10","key":"2990_CR73","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1002\/eji.201040485","volume":"40","author":"V Ablamunits","year":"2010","unstructured":"Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010;40(10):2891\u2013901. https:\/\/doi.org\/10.1002\/eji.201040485.","journal-title":"Eur J Immunol"},{"issue":"6","key":"2990_CR74","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.4049\/jimmunol.172.6.3580","volume":"172","author":"I Takeda","year":"2004","unstructured":"Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, Satomi S, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol. 2004;172(6):3580\u20139. https:\/\/doi.org\/10.4049\/jimmunol.172.6.3580.","journal-title":"J Immunol"},{"issue":"3","key":"2990_CR75","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12016-015-8498-3","volume":"50","author":"GJ Webb","year":"2016","unstructured":"Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and Autoimmunity: a Comprehensive Review. Clin Rev Allergy Immunol. 2016;50(3):312\u201332. https:\/\/doi.org\/10.1007\/s12016-015-8498-3.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2990_CR76","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/ni1030","volume":"5","author":"J Song","year":"2004","unstructured":"Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol. 2004;5(2):150\u20138. https:\/\/doi.org\/10.1038\/ni1030.","journal-title":"Nat Immunol"},{"issue":"3","key":"2990_CR77","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s1074-7613(01)00191-1","volume":"15","author":"PR Rogers","year":"2001","unstructured":"Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001;15(3):445\u201355. https:\/\/doi.org\/10.1016\/s1074-7613(01)00191-1.","journal-title":"Immunity"},{"issue":"7","key":"2990_CR78","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/blood-2004-07-2959","volume":"105","author":"B Valzasina","year":"2005","unstructured":"Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. Triggering of OX40 (CD134) on CD4(+)CD25\u2009+\u2009T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood. 2005;105(7):2845\u201351. https:\/\/doi.org\/10.1182\/blood-2004-07-2959.","journal-title":"Blood"},{"issue":"7","key":"2990_CR79","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood-2007-01-070748","volume":"110","author":"MD Vu","year":"2007","unstructured":"Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, et al. OX40 costimulation turns off Foxp3\u2009+\u2009Tregs. Blood. 2007;110(7):2501\u201310. https:\/\/doi.org\/10.1182\/blood-2007-01-070748.","journal-title":"Blood"},{"issue":"5","key":"2990_CR80","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.4049\/jimmunol.181.5.3193","volume":"181","author":"X Xiao","year":"2008","unstructured":"Xiao X, Kroemer A, Gao W, Ishii N, Demirci G, Li XC. OX40\/OX40L costimulation affects induction of Foxp3\u2009+\u2009regulatory T cells in part by expanding memory T cells in vivo. J Immunol. 2008;181(5):3193\u2013201. https:\/\/doi.org\/10.4049\/jimmunol.181.5.3193.","journal-title":"J Immunol"},{"key":"2990_CR81","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","volume":"28","author":"M Croft","year":"2010","unstructured":"Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57\u201378. https:\/\/doi.org\/10.1146\/annurev-immunol-030409-101243.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2990_CR82","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.4049\/jimmunol.179.3.1427","volume":"179","author":"T So","year":"2007","unstructured":"So T, Croft M. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25\u2009+\u2009Foxp3+ T cells. J Immunol. 2007;179(3):1427\u201330. https:\/\/doi.org\/10.4049\/jimmunol.179.3.1427.","journal-title":"J Immunol"},{"issue":"35","key":"2990_CR83","doi-asserted-by":"publisher","first-page":"13138","DOI":"10.1073\/pnas.0603107103","volume":"103","author":"T Ito","year":"2006","unstructured":"Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, Gilliet M, et al. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci U S A. 2006;103(35):13138\u201343. https:\/\/doi.org\/10.1073\/pnas.0603107103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2990_CR84","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.celrep.2018.06.052","volume":"24","author":"X Zhang","year":"2018","unstructured":"Zhang X, Xiao X, Lan P, Li J, Dou Y, Chen W, et al. OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms. Cell Rep. 2018;24(3):607\u201318. https:\/\/doi.org\/10.1016\/j.celrep.2018.06.052.","journal-title":"Cell Rep"},{"issue":"10","key":"2990_CR85","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/eji.201040505","volume":"40","author":"S Piconese","year":"2010","unstructured":"Piconese S, Pittoni P, Burocchi A, Gorzanelli A, Care A, Tripodo C, et al. A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. Eur J Immunol. 2010;40(10):2902\u201313. https:\/\/doi.org\/10.1002\/eji.201040505.","journal-title":"Eur J Immunol"},{"issue":"7","key":"2990_CR86","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.4049\/jimmunol.1202752","volume":"191","author":"KS Voo","year":"2013","unstructured":"Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, et al. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013;191(7):3641\u201350. https:\/\/doi.org\/10.4049\/jimmunol.1202752.","journal-title":"J Immunol"},{"issue":"5","key":"2990_CR87","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2141.2004.05108.x","volume":"126","author":"J Sanchez","year":"2004","unstructured":"Sanchez J, Casano J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F, et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2004;126(5):697\u2013703. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05108.x.","journal-title":"Br J Haematol"},{"key":"2990_CR88","doi-asserted-by":"publisher","unstructured":"Tkachev V, Furlan SN, Watkins B, Hunt DJ, Zheng HB, Panoskaltsis-Mortari A, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving T(reg) reconstitution after transplant. Sci Transl Med. 2017;9(408). https:\/\/doi.org\/10.1126\/scitranslmed.aan3085.","DOI":"10.1126\/scitranslmed.aan3085"},{"issue":"5","key":"2990_CR89","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/cpt.2539","volume":"111","author":"M Saghari","year":"2022","unstructured":"Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022;111(5):1121\u201332. https:\/\/doi.org\/10.1002\/cpt.2539.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2990_CR90","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bjd\/ljad240","volume":"189","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189(5):531\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljad240.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2990_CR91","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1038\/s41598-017-05254-8","volume":"7","author":"K Alharshawi","year":"2017","unstructured":"Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Bhattacharya P, Sun Z, et al. PKC-\u0473 is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells. Sci Rep. 2017;7(1):6594. https:\/\/doi.org\/10.1038\/s41598-017-05254-8.","journal-title":"Sci Rep"},{"issue":"2","key":"2990_CR92","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4049\/jimmunol.1101373","volume":"188","author":"X Xiao","year":"2012","unstructured":"Xiao X, Gong W, Demirci G, Liu W, Spoerl S, Chu X, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012;188(2):892\u2013901. https:\/\/doi.org\/10.4049\/jimmunol.1101373.","journal-title":"J Immunol"},{"key":"2990_CR93","doi-asserted-by":"publisher","first-page":"39751","DOI":"10.1038\/srep39751","volume":"7","author":"P Kumar","year":"2017","unstructured":"Kumar P, Alharshawi K, Bhattacharya P, Marinelarena A, Haddad C, Sun Z, et al. Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling. Sci Rep. 2017;7:39751. https:\/\/doi.org\/10.1038\/srep39751.","journal-title":"Sci Rep"},{"issue":"11","key":"2990_CR94","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.4049\/jimmunol.1202298","volume":"190","author":"A Gopisetty","year":"2013","unstructured":"Gopisetty A, Bhattacharya P, Haddad C, Bruno JC Jr., Vasu C, Miele L, et al. OX40L\/Jagged1 cosignaling by GM-CSF-induced bone marrow-derived dendritic cells is required for the expansion of functional regulatory T cells. J Immunol. 2013;190(11):5516\u201325. https:\/\/doi.org\/10.4049\/jimmunol.1202298.","journal-title":"J Immunol"},{"issue":"1","key":"2990_CR95","doi-asserted-by":"publisher","first-page":"14940","DOI":"10.1038\/s41598-018-33307-z","volume":"8","author":"A Marinelarena","year":"2018","unstructured":"Marinelarena A, Bhattacharya P, Kumar P, Maker AV, Prabhakar BS. Identification of a Novel OX40L(+) Dendritic Cell Subset That Selectively Expands Regulatory T cells. Sci Rep. 2018;8(1):14940. https:\/\/doi.org\/10.1038\/s41598-018-33307-z.","journal-title":"Sci Rep"},{"issue":"8","key":"2990_CR96","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.4049\/jimmunol.0901112","volume":"183","author":"CE Ruby","year":"2009","unstructured":"Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, et al. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol. 2009;183(8):4853\u20137. https:\/\/doi.org\/10.4049\/jimmunol.0901112.","journal-title":"J Immunol"},{"issue":"7","key":"2990_CR97","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.1900696","volume":"203","author":"F Polesso","year":"2019","unstructured":"Polesso F, Sarker M, Weinberg AD, Murray SE, Moran AE. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function. J Immunol. 2019;203(7):2011\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1900696.","journal-title":"J Immunol"},{"issue":"2","key":"2990_CR98","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/cmi.2018.8","volume":"16","author":"P Kumar","year":"2019","unstructured":"Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, et al. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cell Mol Immunol. 2019;16(2):138\u201353. https:\/\/doi.org\/10.1038\/cmi.2018.8.","journal-title":"Cell Mol Immunol"},{"key":"2990_CR99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-065x.1996.tb00920.x","volume":"153","author":"SW Van Gool","year":"1996","unstructured":"Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev. 1996;153:47\u201383. https:\/\/doi.org\/10.1111\/j.1600-065x.1996.tb00920.x.","journal-title":"Immunol Rev"},{"issue":"2","key":"2990_CR100","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1084\/jem.184.2.747","volume":"184","author":"M Cella","year":"1996","unstructured":"Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2):747\u201352. https:\/\/doi.org\/10.1084\/jem.184.2.747.","journal-title":"J Exp Med"},{"issue":"6581","key":"2990_CR101","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/381434a0","volume":"381","author":"CP Larsen","year":"1996","unstructured":"Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434\u20138. https:\/\/doi.org\/10.1038\/381434a0.","journal-title":"Nature"},{"key":"2990_CR102","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.22.012703.104533","volume":"22","author":"SA Quezada","year":"2004","unstructured":"Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40\/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307\u201328. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104533.","journal-title":"Annu Rev Immunol"},{"issue":"24","key":"2990_CR103","doi-asserted-by":"publisher","first-page":"13967","DOI":"10.1073\/pnas.93.24.13967","volume":"93","author":"WW Hancock","year":"1996","unstructured":"Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A. 1996;93(24):13967\u201372. https:\/\/doi.org\/10.1073\/pnas.93.24.13967.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2990_CR104","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1097\/TP.0b013e3181d3c9d4","volume":"89","author":"DG Lim","year":"2010","unstructured":"Lim DG, Koo SK, Park YH, Kim Y, Kim HM, Park CS, et al. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4\u2009+\u2009CD25+Foxp3\u2009+\u2009regulatory T cells in allotransplantation. Transplantation. 2010;89(8):928\u201336. https:\/\/doi.org\/10.1097\/TP.0b013e3181d3c9d4.","journal-title":"Transplantation"},{"issue":"9","key":"2990_CR105","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.4049\/jimmunol.163.9.4805","volume":"163","author":"K Honey","year":"1999","unstructured":"Honey K, Cobbold SP, Waldmann H. CD40 ligand blockade induces CD4\u2009+\u2009T cell tolerance and linked suppression. J Immunol. 1999;163(9):4805\u201310.","journal-title":"J Immunol"},{"issue":"9","key":"2990_CR106","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/01.Tp.0000083557.25887.Ee","volume":"76","author":"W Sun","year":"2003","unstructured":"Sun W, Wang Q, Zhang L, Liu Y, Zhang M, Wang C, et al. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Transplantation. 2003;76(9):1351\u20139. https:\/\/doi.org\/10.1097\/01.Tp.0000083557.25887.Ee.","journal-title":"Transplantation"},{"issue":"4","key":"2990_CR107","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/eji.201242737","volume":"43","author":"I Vogel","year":"2013","unstructured":"Vogel I, Verbinnen B, Maes W, Boon L, Van Gool SW, Ceuppens JL. Foxp3\u2009+\u2009regulatory T cells are activated in spite of B7-CD28 and CD40-CD40L blockade. Eur J Immunol. 2013;43(4):1013\u201323. https:\/\/doi.org\/10.1002\/eji.201242737.","journal-title":"Eur J Immunol"},{"key":"2990_CR108","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3389\/fimmu.2019.00306","volume":"10","author":"H Liu","year":"2019","unstructured":"Liu H, Qiu F, Wang Y, Zeng Q, Liu C, Chen Y, et al. CD8\u2009+\u2009CD122+PD-1\u2009+\u2009Tregs Synergize With Costimulatory Blockade of CD40\/CD154, but Not B7\/CD28, to Prolong Murine Allograft Survival. Front Immunol. 2019;10:306. https:\/\/doi.org\/10.3389\/fimmu.2019.00306.","journal-title":"Front Immunol"},{"issue":"4","key":"2990_CR109","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1172\/jci28801","volume":"117","author":"C Guillonneau","year":"2007","unstructured":"Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Herv\u00e9 C, Li XL, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117(4):1096\u2013106. https:\/\/doi.org\/10.1172\/jci28801.","journal-title":"J Clin Invest"},{"issue":"4","key":"2990_CR110","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/intimm\/dxp005","volume":"21","author":"K Nagahama","year":"2009","unstructured":"Nagahama K, Fehervari Z, Oida T, Yamaguchi T, Ogawa O, Sakaguchi S. Differential control of allo-antigen-specific regulatory T cells and effector T cells by anti-CD4 and other agents in establishing transplantation tolerance. Int Immunol. 2009;21(4):379\u201391. https:\/\/doi.org\/10.1093\/intimm\/dxp005.","journal-title":"Int Immunol"},{"issue":"7","key":"2990_CR111","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/eji.201545455","volume":"45","author":"JG Chai","year":"2015","unstructured":"Chai JG, Ratnasothy K, Bucy RP, Noelle RJ, Lechler R, Lombardi G. Allospecific CD4(+) T cells retain effector function and are actively regulated by Treg cells in the context of transplantation tolerance. Eur J Immunol. 2015;45(7):2017\u201327. https:\/\/doi.org\/10.1002\/eji.201545455.","journal-title":"Eur J Immunol"},{"issue":"11","key":"2990_CR112","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1111\/ajt.12417","volume":"13","author":"DF Pinelli","year":"2013","unstructured":"Pinelli DF, Wagener ME, Liu D, Yamniuk A, Tamura J, Grant S, et al. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. Am J Transpl. 2013;13(11):3021\u201330. https:\/\/doi.org\/10.1111\/ajt.12417.","journal-title":"Am J Transpl"},{"key":"2990_CR113","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fimmu.2017.00421","volume":"8","author":"L Govender","year":"2017","unstructured":"Govender L, Wyss JC, Kumar R, Pascual M, Golshayan D. IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154-CD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized Mice. Front Immunol. 2017;8:421. https:\/\/doi.org\/10.3389\/fimmu.2017.00421.","journal-title":"Front Immunol"},{"issue":"3","key":"2990_CR114","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/cei.13537","volume":"203","author":"P Alonso-Guallart","year":"2021","unstructured":"Alonso-Guallart P, Llore N, Lopes E, Kofman SB, Ho SH, Stern J, et al. CD40L-stimulated B cells for ex-vivo expansion of polyspecific non-human primate regulatory T cells for translational studies. Clin Exp Immunol. 2021;203(3):480\u201392. https:\/\/doi.org\/10.1111\/cei.13537.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2990_CR115","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41598-018-19621-6","volume":"8","author":"JM Mathew","year":"2018","unstructured":"Mathew JM, Voss JH, McEwen ST, Konieczna I, Chakraborty A, Huang X, et al. Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance. Sci Rep. 2018;8(1):1136. https:\/\/doi.org\/10.1038\/s41598-018-19621-6.","journal-title":"Sci Rep"},{"issue":"168","key":"2990_CR116","doi-asserted-by":"publisher","first-page":"168ra9","DOI":"10.1126\/scitranslmed.3004943","volume":"5","author":"J Zheng","year":"2013","unstructured":"Zheng J, Liu Y, Liu Y, Liu M, Xiang Z, Lam KT, et al. Human CD8\u2009+\u2009regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med. 2013;5(168):168ra9. https:\/\/doi.org\/10.1126\/scitranslmed.3004943.","journal-title":"Sci Transl Med"},{"issue":"6","key":"2990_CR117","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.4049\/jimmunol.0901329","volume":"183","author":"J Zheng","year":"2009","unstructured":"Zheng J, Liu Y, Qin G, Chan PL, Mao H, Lam KT, et al. Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells. J Immunol. 2009;183(6):3742\u201350. https:\/\/doi.org\/10.4049\/jimmunol.0901329.","journal-title":"J Immunol"},{"issue":"1","key":"2990_CR118","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.1365-2249.2002.01857.x","volume":"129","author":"J Ohata","year":"2002","unstructured":"Ohata J, Sakurai J, Saito K, Tani K, Asano S, Azuma M. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Clin Exp Immunol. 2002;129(1):61\u20138. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01857.x.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2990_CR119","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0301-472x(02)01009-3","volume":"31","author":"TB Prigozhina","year":"2003","unstructured":"Prigozhina TB, Gurevitch O, Elkin G, Morecki S, Yakovlev E, Slavin S. CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. Exp Hematol. 2003;31(1):81\u20138. https:\/\/doi.org\/10.1016\/s0301-472x(02)01009-3.","journal-title":"Exp Hematol"},{"key":"2990_CR120","doi-asserted-by":"publisher","first-page":"986859","DOI":"10.1155\/2013\/986859","volume":"2013","author":"KT Krill","year":"2013","unstructured":"Krill KT, Csencsits-Smith K, Wood SC, Faust S, Lu G, Bishop DK. Glucocorticoid-induced TNFR-related protein stimulation reverses cardiac allograft acceptance induced by CD40-CD40L blockade. Clin Dev Immunol. 2013;2013:986859. https:\/\/doi.org\/10.1155\/2013\/986859.","journal-title":"Clin Dev Immunol"},{"issue":"6805","key":"2990_CR121","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/35037728","volume":"407","author":"PH Krammer","year":"2000","unstructured":"Krammer PH. CD95\u2019s deadly mission in the immune system. Nature. 2000;407(6805):789\u201395. https:\/\/doi.org\/10.1038\/35037728.","journal-title":"Nature"},{"key":"2990_CR122","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1034\/j.1600-065x.2003.00051.x","volume":"193","author":"DR Green","year":"2003","unstructured":"Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev. 2003;193:70\u201381. https:\/\/doi.org\/10.1034\/j.1600-065x.2003.00051.x.","journal-title":"Immunol Rev"},{"issue":"1","key":"2990_CR123","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/sj.cdd.4401186","volume":"10","author":"ME Peter","year":"2003","unstructured":"Peter ME, Krammer PH. The CD95(APO-1\/Fas) DISC and beyond. Cell Death Differ. 2003;10(1):26\u201335. https:\/\/doi.org\/10.1038\/sj.cdd.4401186.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2990_CR124","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0092-8674(00)00119-7","volume":"103","author":"SW Fesik","year":"2000","unstructured":"Fesik SW. Insights into programmed cell death through structural biology. Cell. 2000;103(2):273\u201382. https:\/\/doi.org\/10.1016\/s0092-8674(00)00119-7.","journal-title":"Cell"},{"issue":"10","key":"2990_CR125","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2006-02-005660","volume":"108","author":"B Fritzsching","year":"2006","unstructured":"Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, et al. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood. 2006;108(10):3371\u20138. https:\/\/doi.org\/10.1182\/blood-2006-02-005660.","journal-title":"Blood"},{"issue":"4","key":"2990_CR126","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.4049\/jimmunol.1002321","volume":"187","author":"EM Weiss","year":"2011","unstructured":"Weiss EM, Schmidt A, Vobis D, Garbi N, Lahl K, Mayer CT, et al. Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells. J Immunol. 2011;187(4):1684\u201391. https:\/\/doi.org\/10.4049\/jimmunol.1002321.","journal-title":"J Immunol"},{"issue":"12","key":"2990_CR127","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.4049\/jimmunol.175.12.8392","volume":"175","author":"M Miyara","year":"2005","unstructured":"Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol. 2005;175(12):8392\u2013400. https:\/\/doi.org\/10.4049\/jimmunol.175.12.8392.","journal-title":"J Immunol"},{"issue":"10","key":"2990_CR128","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jcyt.2013.05.021","volume":"15","author":"W Zhang","year":"2013","unstructured":"Zhang W, Nair S, Danby R, Peniket A, Roberts DJ. Selective depletion of FOXP3(high) cells by Fas-Fas-L-induced apoptosis occurs in CD4(+)CD25(+)-enriched populations during repeated expansion. Cytotherapy. 2013;15(10):1286\u201396. https:\/\/doi.org\/10.1016\/j.jcyt.2013.05.021.","journal-title":"Cytotherapy"},{"issue":"8","key":"2990_CR129","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.4049\/jimmunol.178.8.4891","volume":"178","author":"D Baatar","year":"2007","unstructured":"Baatar D, Olkhanud P, Sumitomo K, Taub D, Gress R, Biragyn A. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4\u2009+\u2009Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol. 2007;178(8):4891\u2013900. https:\/\/doi.org\/10.4049\/jimmunol.178.8.4891.","journal-title":"J Immunol"},{"issue":"10","key":"2990_CR130","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.exphem.2013.04.016","volume":"41","author":"ES Yolcu","year":"2013","unstructured":"Yolcu ES, Kaminitz A, Mizrahi K, Ash S, Yaniv I, Stein J, et al. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease. Exp Hematol. 2013;41(10):903\u201311. https:\/\/doi.org\/10.1016\/j.exphem.2013.04.016.","journal-title":"Exp Hematol"},{"issue":"2","key":"2990_CR131","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4049\/jimmunol.181.2.931","volume":"181","author":"ES Yolcu","year":"2008","unstructured":"Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, et al. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J Immunol. 2008;181(2):931\u20139. https:\/\/doi.org\/10.4049\/jimmunol.181.2.931.","journal-title":"J Immunol"},{"issue":"11","key":"2990_CR132","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1161\/01.cir.0000064893.96179.7e","volume":"107","author":"N Askenasy","year":"2003","unstructured":"Askenasy N, Yolcu ES, Wang Z, Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation. 2003;107(11):1525\u201331. https:\/\/doi.org\/10.1161\/01.cir.0000064893.96179.7e.","journal-title":"Circulation"},{"issue":"1","key":"2990_CR133","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1038\/s41467-024-49135-x","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Huang R, Lu Y, Liu M, Mo R. Immuno-protective vesicle-crosslinked hydrogel for allogenic transplantation. Nat Commun. 2024;15(1):5176. https:\/\/doi.org\/10.1038\/s41467-024-49135-x.","journal-title":"Nat Commun"},{"issue":"7","key":"2990_CR134","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood.2019001347","volume":"136","author":"SP Lim","year":"2020","unstructured":"Lim SP, Costantini B, Mian SA, Perez Abellan P, Gandhi S, Martinez Llordella M, et al. Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction. Blood. 2020;136(7):885\u201397. https:\/\/doi.org\/10.1182\/blood.2019001347.","journal-title":"Blood"},{"issue":"1","key":"2990_CR135","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2567.2006.02550.x","volume":"121","author":"RC Duggleby","year":"2007","unstructured":"Duggleby RC, Shaw TN, Jarvis LB, Kaur G, Gaston JS. CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4\u2009+\u2009CD25+ cells. Immunology. 2007;121(1):129\u201339. https:\/\/doi.org\/10.1111\/j.1365-2567.2006.02550.x.","journal-title":"Immunology"},{"issue":"3","key":"2990_CR136","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1182\/blood-2005-07-3032","volume":"107","author":"JJ Coenen","year":"2006","unstructured":"Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27\u2009+\u2009subset of human CD4\u2009+\u2009CD25+ regulatory T cells. Blood. 2006;107(3):1018\u201323. https:\/\/doi.org\/10.1182\/blood-2005-07-3032.","journal-title":"Blood"},{"issue":"14","key":"2990_CR137","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","volume":"72","author":"C Claus","year":"2012","unstructured":"Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 2012;72(14):3664\u201376. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2791.","journal-title":"Cancer Res"},{"issue":"10","key":"2990_CR138","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.4049\/jimmunol.1700380","volume":"199","author":"RE O\u2019Neill","year":"2017","unstructured":"O\u2019Neill RE, Du W, Mohammadpour H, Alqassim E, Qiu J, Chen G, et al. T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses. J Immunol. 2017;199(10):3700\u201310. https:\/\/doi.org\/10.4049\/jimmunol.1700380.","journal-title":"J Immunol"},{"issue":"3","key":"2990_CR139","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.4049\/jimmunol.174.3.1357","volume":"174","author":"A Yamada","year":"2005","unstructured":"Yamada A, Salama AD, Sho M, Najafian N, Ito T, Forman JP, et al. CD70 signaling is critical for CD28-independent CD8\u2009+\u2009T cell-mediated alloimmune responses in vivo. J Immunol. 2005;174(3):1357\u201364. https:\/\/doi.org\/10.4049\/jimmunol.174.3.1357.","journal-title":"J Immunol"},{"issue":"5","key":"2990_CR140","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1365-3083.2011.02595.x","volume":"74","author":"W Shao","year":"2011","unstructured":"Shao W, Yan G, Lin Y, Chen J, Dai H, Wang F, et al. CD44\/CD70 blockade and anti-CD154\/LFA-1 treatment synergistically suppress accelerated rejection and prolong cardiac allograft survival in mice. Scand J Immunol. 2011;74(5):430\u20137. https:\/\/doi.org\/10.1111\/j.1365-3083.2011.02595.x.","journal-title":"Scand J Immunol"},{"issue":"2","key":"2990_CR141","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.imlet.2011.03.009","volume":"138","author":"W Shao","year":"2011","unstructured":"Shao W, Chen J, Dai H, Peng Y, Wang F, Xia J, et al. Combination of monoclonal antibodies with DST inhibits accelerated rejection mediated by memory T cells to induce long-lived heart allograft acceptance in mice. Immunol Lett. 2011;138(2):122\u20138. https:\/\/doi.org\/10.1016\/j.imlet.2011.03.009.","journal-title":"Immunol Lett"},{"issue":"12","key":"2990_CR142","doi-asserted-by":"publisher","first-page":"7573","DOI":"10.4049\/jimmunol.174.12.7573","volume":"174","author":"HJ Koenen","year":"2005","unstructured":"Koenen HJ, Fasse E, Joosten I. CD27\/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol. 2005;174(12):7573\u201383. https:\/\/doi.org\/10.4049\/jimmunol.174.12.7573.","journal-title":"J Immunol"},{"issue":"37","key":"2990_CR143","doi-asserted-by":"publisher","first-page":"eadw1702","DOI":"10.1126\/sciadv.adw1702","volume":"11","author":"H Guo","year":"2025","unstructured":"Guo H, Wang B, Wu Z, Zhang Q, Jiang X, Zhang F, et al. CD8(+)HLA-DR(+)CD27(+) T cells define a population of naturally occurring regulatory precursors in humans. Sci Adv. 2025;11(37):eadw1702. https:\/\/doi.org\/10.1126\/sciadv.adw1702.","journal-title":"Sci Adv"},{"issue":"11","key":"2990_CR144","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.4049\/jimmunol.179.11.7295","volume":"179","author":"KG Elpek","year":"2007","unstructured":"Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4\u2009+\u2009CD25+FoxP3\u2009+\u2009T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol. 2007;179(11):7295\u2013304. https:\/\/doi.org\/10.4049\/jimmunol.179.11.7295.","journal-title":"J Immunol"},{"issue":"1","key":"2990_CR145","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bbmt.2011.09.004","volume":"18","author":"J Kim","year":"2012","unstructured":"Kim J, Kim W, Kim HJ, Park S, Kim HA, Jung D, et al. Host CD25\u2009+\u2009CD4+Foxp3\u2009+\u2009regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease. Biol Blood Marrow Transpl. 2012;18(1):44\u201354. https:\/\/doi.org\/10.1016\/j.bbmt.2011.09.004.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2990_CR146","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1084\/jem.20132687","volume":"211","author":"S Madireddi","year":"2014","unstructured":"Madireddi S, Eun S-Y, Lee S-W, Nem\u010dovi\u010dov\u00e1 I, Mehta AK, Zajonc DM, et al. Galectin-9 controls the therapeutic activity of 4-1BB\u2013targeting antibodies. J Exp Med. 2014;211(7):1433\u201348. https:\/\/doi.org\/10.1084\/jem.20132687.","journal-title":"J Exp Med"},{"issue":"8","key":"2990_CR147","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.4049\/jimmunol.1700575","volume":"199","author":"S Madireddi","year":"2017","unstructured":"Madireddi S, Eun SY, Mehta AK, Birta A, Zajonc DM, Niki T, et al. Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9. J Immunol. 2017;199(8):2721\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1700575.","journal-title":"J Immunol"},{"key":"2990_CR148","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3389\/fimmu.2018.00199","volume":"9","author":"A Nowak","year":"2018","unstructured":"Nowak A, Lock D, Bacher P, Hohnstein T, Vogt K, Gottfreund J, et al. CD137\u2009+\u2009CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures. Front Immunol. 2018;9:199. https:\/\/doi.org\/10.3389\/fimmu.2018.00199.","journal-title":"Front Immunol"},{"issue":"5","key":"2990_CR149","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.4049\/jimmunol.166.5.3174","volume":"166","author":"BR Blazar","year":"2001","unstructured":"Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol. 2001;166(5):3174\u201383. https:\/\/doi.org\/10.4049\/jimmunol.166.5.3174.","journal-title":"J Immunol"},{"issue":"2","key":"2990_CR150","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/icb.2012.74","volume":"91","author":"MC St Rose","year":"2013","unstructured":"St Rose MC, Taylor RA, Bandyopadhyay S, Qui HZ, Hagymasi AT, Vella AT, et al. CD134\/CD137 dual costimulation-elicited IFN-gamma maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol. 2013;91(2):173\u201383. https:\/\/doi.org\/10.1038\/icb.2012.74.","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"2990_CR151","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ni759","volume":"3","author":"J Shimizu","year":"2002","unstructured":"Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3(2):135\u201342. https:\/\/doi.org\/10.1038\/ni759.","journal-title":"Nat Immunol"},{"issue":"2","key":"2990_CR152","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/s1074-7613(02)00280-7","volume":"16","author":"RS McHugh","year":"2002","unstructured":"McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16(2):311\u201323. https:\/\/doi.org\/10.1016\/s1074-7613(02)00280-7.","journal-title":"Immunity"},{"key":"2990_CR153","doi-asserted-by":"publisher","unstructured":"Li Z, Mahesh SP, Kim BJ, Buggage RR, Nussenblatt RB. Expression of glucocorticoid induced TNF receptor family related protein (GITR) on peripheral T cells from normal human donors and patients with non-infectious uveitis. J Autoimmun. 2003;21(1):83\u201392. https:\/\/doi.org\/10.1016\/s0896-8411(03)00085.","DOI":"10.1016\/s0896-8411(03)00085"},{"issue":"9","key":"2990_CR154","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1369\/jhc.6A7119.2007","volume":"55","author":"OJ de Boer","year":"2007","unstructured":"de Boer OJ, van der Loos CM, Teeling P, van der Wal AC, Teunissen MB. Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4\u2009+\u2009CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem. 2007;55(9):891\u20138. https:\/\/doi.org\/10.1369\/jhc.6A7119.2007.","journal-title":"J Histochem Cytochem"},{"issue":"9","key":"2990_CR155","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood-2005-08-3419","volume":"107","author":"S Hanabuchi","year":"2006","unstructured":"Hanabuchi S, Watanabe N, Wang YH, Wang YH, Ito T, Shaw J, et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood. 2006;107(9):3617\u201323. https:\/\/doi.org\/10.1182\/blood-2005-08-3419.","journal-title":"Blood"},{"issue":"4","key":"2990_CR156","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s0960-9822(99)80093-1","volume":"9","author":"AL Gurney","year":"1999","unstructured":"Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, Baldwin DT, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol. 1999;9(4):215\u20138. https:\/\/doi.org\/10.1016\/s0960-9822(99)80093-1.","journal-title":"Curr Biol"},{"issue":"25","key":"2990_CR157","doi-asserted-by":"publisher","first-page":"15059","DOI":"10.1073\/pnas.2334901100","volume":"100","author":"M Tone","year":"2003","unstructured":"Tone M, Tone Y, Adams E, Yates SF, Frewin MR, Cobbold SP, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A. 2003;100(25):15059\u201364. https:\/\/doi.org\/10.1073\/pnas.2334901100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2990_CR158","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.4049\/jimmunol.0802751","volume":"182","author":"RW van Olffen","year":"2009","unstructured":"van Olffen RW, Koning N, van Gisbergen KP, Wensveen FM, Hoek RM, Boon L, et al. GITR triggering induces expansion of both effector and regulatory CD4\u2009+\u2009T cells in vivo. J Immunol. 2009;182(12):7490\u2013500. https:\/\/doi.org\/10.4049\/jimmunol.0802751.","journal-title":"J Immunol"},{"issue":"4","key":"2990_CR159","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.bbrc.2008.03.024","volume":"369","author":"H Igarashi","year":"2008","unstructured":"Igarashi H, Cao Y, Iwai H, Piao J, Kamimura Y, Hashiguchi M, et al. GITR ligand-costimulation activates effector and regulatory functions of CD4\u2009+\u2009T cells. Biochem Biophys Res Commun. 2008;369(4):1134\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2008.03.024.","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"2990_CR160","doi-asserted-by":"publisher","first-page":"8559","DOI":"10.1074\/jbc.M512915200","volume":"281","author":"EM Esparza","year":"2006","unstructured":"Esparza EM, Lindsten T, Stockhausen JM, Arch RH. Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells. J Biol Chem. 2006;281(13):8559\u201364. https:\/\/doi.org\/10.1074\/jbc.M512915200.","journal-title":"J Biol Chem"},{"issue":"1","key":"2990_CR161","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cellimm.2005.07.002","volume":"235","author":"AP Kohm","year":"2005","unstructured":"Kohm AP, Podojil JR, Williams JS, McMahon JS, Miller SD. CD28 regulates glucocorticoid-induced TNF receptor family-related gene expression on CD4\u2009+\u2009T cells via IL-2-dependent mechanisms. Cell Immunol. 2005;235(1):56\u201364. https:\/\/doi.org\/10.1016\/j.cellimm.2005.07.002.","journal-title":"Cell Immunol"},{"issue":"5","key":"2990_CR162","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/ni.2849","volume":"15","author":"SA Mahmud","year":"2014","unstructured":"Mahmud SA, Manlove LS, Schmitz HM, Xing Y, Wang Y, Owen DL, et al. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol. 2014;15(5):473\u201381. https:\/\/doi.org\/10.1038\/ni.2849.","journal-title":"Nat Immunol"},{"issue":"4","key":"2990_CR163","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ni909","volume":"4","author":"R Khattri","year":"2003","unstructured":"Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4\u2009+\u2009CD25+ T regulatory cells. Nat Immunol. 2003;4(4):337\u201342. https:\/\/doi.org\/10.1038\/ni909.","journal-title":"Nat Immunol"},{"issue":"21","key":"2990_CR164","doi-asserted-by":"publisher","first-page":"17100","DOI":"10.1074\/jbc.M111.316943","volume":"287","author":"A Joetham","year":"2012","unstructured":"Joetham A, Ohnishi H, Okamoto M, Takeda K, Schedel M, Domenico J, et al. Loss of T regulatory cell suppression following signaling through glucocorticoid-induced tumor necrosis receptor (GITR) is dependent on c-Jun N-terminal kinase activation. J Biol Chem. 2012;287(21):17100\u20138. https:\/\/doi.org\/10.1074\/jbc.M111.316943.","journal-title":"J Biol Chem"},{"issue":"12","key":"2990_CR165","doi-asserted-by":"publisher","first-page":"21674","DOI":"10.3390\/ijms151221674","volume":"15","author":"Y Liu","year":"2014","unstructured":"Liu Y, Tang X, Tian J, Zhu C, Peng H, Rui K, et al. Th17\/Treg cells imbalance and GITRL profile in patients with Hashimoto\u2019s thyroiditis. Int J Mol Sci. 2014;15(12):21674\u201386. https:\/\/doi.org\/10.3390\/ijms151221674.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2990_CR166","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1002\/eji.201343451","volume":"43","author":"A Ephrem","year":"2013","unstructured":"Ephrem A, Epstein AL, Stephens GL, Thornton AM, Glass D, Shevach EM. Modulation of Treg cells\/T effector function by GITR signaling is context-dependent. Eur J Immunol. 2013;43(9):2421\u20139. https:\/\/doi.org\/10.1002\/eji.201343451.","journal-title":"Eur J Immunol"},{"issue":"18","key":"2990_CR167","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-22-1489","volume":"28","author":"T Hernandez-Guerrero","year":"2022","unstructured":"Hernandez-Guerrero T, Moreno V. GITR Antibodies in Cancer: Not Ready for Prime Time. Clin Cancer Res. 2022;28(18):3905\u20137. 10.1158\/1078\u2009\u2013\u20090432.CCR-22-1489.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2990_CR168","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/sj.cdd.4401140","volume":"9","author":"S Spinicelli","year":"2002","unstructured":"Spinicelli S, Nocentini G, Ronchetti S, Krausz LT, Bianchini R, Riccardi C. GITR interacts with the pro-apoptotic protein Siva and induces apoptosis. Cell Death Differ. 2002;9(12):1382\u20134. https:\/\/doi.org\/10.1038\/sj.cdd.4401140.","journal-title":"Cell Death Differ"},{"issue":"8","key":"2990_CR169","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.4049\/jimmunol.173.8.5008","volume":"173","author":"GL Stephens","year":"2004","unstructured":"Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4\u2009+\u2009CD25+ T cells. J Immunol. 2004;173(8):5008\u201320. https:\/\/doi.org\/10.4049\/jimmunol.173.8.5008.","journal-title":"J Immunol"},{"issue":"2","key":"2990_CR170","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cytogfr.2013.12.003","volume":"25","author":"DL Clouthier","year":"2014","unstructured":"Clouthier DL, Watts TH. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev. 2014;25(2):91\u2013106. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.12.003.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"2990_CR171","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.4049\/jimmunol.172.10.5823","volume":"172","author":"HB Ji","year":"2004","unstructured":"Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, Laroux FS, et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol. 2004;172(10):5823\u20137. https:\/\/doi.org\/10.4049\/jimmunol.172.10.5823.","journal-title":"J Immunol"},{"issue":"4","key":"2990_CR172","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/intimm\/dxq001","volume":"22","author":"G Liao","year":"2010","unstructured":"Liao G, Nayak S, Regueiro JR, Berger SB, Detre C, Romero X, et al. GITR engagement preferentially enhances proliferation of functionally competent CD4\u2009+\u2009CD25+FoxP3\u2009+\u2009regulatory T cells. Int Immunol. 2010;22(4):259\u201370. https:\/\/doi.org\/10.1093\/intimm\/dxq001.","journal-title":"Int Immunol"},{"issue":"5","key":"2990_CR173","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13075-014-0444-x","volume":"16","author":"G Nocentini","year":"2014","unstructured":"Nocentini G, Alunno A, Petrillo MG, Bistoni O, Bartoloni E, Caterbi S, et al. Expansion of regulatory GITR+CD25 low\/-CD4\u2009+\u2009T cells in systemic lupus erythematosus patients. Arthritis Res Ther. 2014;16(5):444. https:\/\/doi.org\/10.1186\/s13075-014-0444-x.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2990_CR174","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","volume":"25","author":"R Zappasodi","year":"2019","unstructured":"Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, et al. Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019;25(5):759\u201366. https:\/\/doi.org\/10.1038\/s41591-019-0420-8.","journal-title":"Nat Med"},{"issue":"4","key":"2990_CR175","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1600-6143.2006.01716.x","volume":"7","author":"A Bushell","year":"2007","unstructured":"Bushell A, Wood K. GITR ligation blocks allograft protection by induced CD25\u2009+\u2009CD4+ regulatory T cells without enhancing effector T-cell function. Am J Transpl. 2007;7(4):759\u201368. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01716.x.","journal-title":"Am J Transpl"},{"issue":"5","key":"2990_CR176","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.4049\/jimmunol.1501877","volume":"196","author":"DJ Nowakowska","year":"2016","unstructured":"Nowakowska DJ, Kissler S. Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation. J Immunol. 2016;196(5):2145\u201352. https:\/\/doi.org\/10.4049\/jimmunol.1501877.","journal-title":"J Immunol"},{"issue":"8","key":"2990_CR177","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/1873-3468.12632","volume":"591","author":"S Bittner","year":"2017","unstructured":"Bittner S, Knoll G, Ehrenschwender M. Death receptor 3 signaling enhances proliferation of human regulatory T cells. FEBS Lett. 2017;591(8):1187\u201395. https:\/\/doi.org\/10.1002\/1873-3468.12632.","journal-title":"FEBS Lett"},{"issue":"4","key":"2990_CR178","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.4049\/jimmunol.1201908","volume":"190","author":"SQ Khan","year":"2013","unstructured":"Khan SQ, Tsai MS, Schreiber TH, Wolf D, Deyev VV, Podack ER. Cloning, expression, and functional characterization of TL1A-Ig. J Immunol. 2013;190(4):1540\u201350. https:\/\/doi.org\/10.4049\/jimmunol.1201908.","journal-title":"J Immunol"},{"issue":"10","key":"2990_CR179","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1172\/JCI42933","volume":"120","author":"TH Schreiber","year":"2010","unstructured":"Schreiber TH, Wolf D, Tsai MS, Chirinos J, Deyev VV, Gonzalez L, et al. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest. 2010;120(10):3629\u201340. https:\/\/doi.org\/10.1172\/JCI42933.","journal-title":"J Clin Invest"},{"issue":"4","key":"2990_CR180","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/ajt.16940","volume":"22","author":"BA Marfil-Garza","year":"2022","unstructured":"Marfil-Garza BA, Pawlick RL, Szeto J, Kroger C, Tahiliani V, Hefler J, et al. Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) agonists in islet transplantation: Endogenous in vivo regulatory T cell expansion promotes prolonged allograft survival. Am J Transpl. 2022;22(4):1101\u201314. https:\/\/doi.org\/10.1111\/ajt.16940.","journal-title":"Am J Transpl"},{"issue":"6","key":"2990_CR181","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/TP.0b013e318264d3ef","volume":"94","author":"D Wolf","year":"2012","unstructured":"Wolf D, Schreiber TH, Tryphonopoulos P, Li S, Tzakis AG, Ruiz P, et al. Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival. Transplantation. 2012;94(6):569\u201374. https:\/\/doi.org\/10.1097\/TP.0b013e318264d3ef.","journal-title":"Transplantation"},{"issue":"2","key":"2990_CR182","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/mi.2010.70","volume":"4","author":"VY Taraban","year":"2011","unstructured":"Taraban VY, Slebioda TJ, Willoughby JE, Buchan SL, James S, Sheth B, et al. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol. 2011;4(2):186\u201396. https:\/\/doi.org\/10.1038\/mi.2010.70.","journal-title":"Mucosal Immunol"},{"issue":"5","key":"2990_CR183","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.bbmt.2017.02.013","volume":"23","author":"D Wolf","year":"2017","unstructured":"Wolf D, Barreras H, Bader CS, Copsel S, Lightbourn CO, Pfeiffer BJ, et al. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2017;23(5):757\u201366. https:\/\/doi.org\/10.1016\/j.bbmt.2017.02.013.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2990_CR184","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.bbmt.2018.04.026","volume":"24","author":"S Copsel","year":"2018","unstructured":"Copsel S, Wolf D, Kale B, Barreras H, Lightbourn CO, Bader CS, et al. Very Low Numbers of CD4(+) FoxP3(+) Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation\/Functional Profile and Suppress GVHD in a Preclinical Model. Biol Blood Marrow Transpl. 2018;24(9):1788\u201394. https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.026.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2990_CR185","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2015-04-637587","volume":"126","author":"BS Kim","year":"2015","unstructured":"Kim BS, Nishikii H, Baker J, Pierini A, Schneidawind D, Pan Y, et al. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. Blood. 2015;126(4):546\u201357. https:\/\/doi.org\/10.1182\/blood-2015-04-637587.","journal-title":"Blood"},{"key":"2990_CR186","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3389\/fimmu.2019.01624","volume":"10","author":"M Mavers","year":"2019","unstructured":"Mavers M, Simonetta F, Nishikii H, Ribado JV, Maas-Bauer K, Alvarez M, et al. Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease. Front Immunol. 2019;10:1624. https:\/\/doi.org\/10.3389\/fimmu.2019.01624.","journal-title":"Front Immunol"},{"issue":"8","key":"2990_CR187","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.4049\/jimmunol.1400481","volume":"193","author":"BM Matta","year":"2014","unstructured":"Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R\/ST2\u2009+\u2009regulatory T cells. J Immunol. 2014;193(8):4010\u201320. https:\/\/doi.org\/10.4049\/jimmunol.1400481.","journal-title":"J Immunol"},{"key":"2990_CR188","doi-asserted-by":"publisher","first-page":"605726","DOI":"10.3389\/fimmu.2021.605726","volume":"12","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Antin JH. GVHD Prophylaxis 2020. Front Immunol. 2021;12:605726. https:\/\/doi.org\/10.3389\/fimmu.2021.605726.","journal-title":"Front Immunol"},{"issue":"10","key":"2990_CR189","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3324\/haematol.2014.109611","volume":"99","author":"Y Inamoto","year":"2014","unstructured":"Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf DJ, Pidala J, et al. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica. 2014;99(10):1618\u201323. https:\/\/doi.org\/10.3324\/haematol.2014.109611.","journal-title":"Haematologica"},{"issue":"4","key":"2990_CR190","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/jco.21.02293","volume":"40","author":"L Luznik","year":"2022","unstructured":"Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, et al. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022;40(4):356\u201368. https:\/\/doi.org\/10.1200\/jco.21.02293.","journal-title":"J Clin Oncol"},{"key":"2990_CR191","doi-asserted-by":"publisher","unstructured":"Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1108188.","DOI":"10.1056\/NEJMoa1108188"},{"issue":"2","key":"2990_CR192","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep.28459","volume":"64","author":"S Todo","year":"2016","unstructured":"Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016;64(2):632\u201343. https:\/\/doi.org\/10.1002\/hep.28459.","journal-title":"Hepatology"},{"issue":"1","key":"2990_CR193","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","volume":"128","author":"J Koreth","year":"2016","unstructured":"Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128(1):130\u20137. https:\/\/doi.org\/10.1182\/blood-2016-02-702852.","journal-title":"Blood"},{"issue":"179","key":"2990_CR194","doi-asserted-by":"publisher","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43. https:\/\/doi.org\/10.1126\/scitranslmed.3005265.","journal-title":"Sci Transl Med"},{"issue":"8","key":"2990_CR195","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016;127(8):1044\u201351. https:\/\/doi.org\/10.1182\/blood-2015-06-653667.","journal-title":"Blood"},{"issue":"3","key":"2990_CR196","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","volume":"117","author":"CG Brunstein","year":"2011","unstructured":"Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061\u201370. https:\/\/doi.org\/10.1182\/blood-2010-07-293795.","journal-title":"Blood"},{"issue":"13","key":"2990_CR197","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2006-06-027409","volume":"108","author":"P Hoffmann","year":"2006","unstructured":"Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, et al. Only the CD45RA+ subpopulation of CD4\u2009+\u2009CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006;108(13):4260\u20137. https:\/\/doi.org\/10.1182\/blood-2006-06-027409.","journal-title":"Blood"},{"key":"2990_CR198","unstructured":"Pharmaceuticals E. Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart: Eledon Pharmaceuticals 2025 [updated Nov 18, 2025. Available from: https:\/\/ir.eledon.com\/news-releases\/news-release-details\/eledon-reports-preliminary-data-first-six-patients-type-1"},{"issue":"5562","key":"2990_CR199","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097\u2013100. https:\/\/doi.org\/10.1126\/science.1068440.","journal-title":"Science"},{"issue":"11","key":"2990_CR200","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2174\/1568009623666230523155808","volume":"23","author":"T Bakhtiari","year":"2023","unstructured":"Bakhtiari T, Ahmadvand M, Salmaninejad A, Ghaderi A, Yaghmaie M, Sadeghi A, et al. The Influence of KIR Gene Polymorphisms and KIR-ligand Binding on Outcomes in Hematologic Malignancies following Haploidentical Stem Cell Transplantation: A Comprehensive Review. Curr Cancer Drug Targets. 2023;23(11):868\u201378. https:\/\/doi.org\/10.2174\/1568009623666230523155808.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6013","key":"2990_CR201","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44\u20139. https:\/\/doi.org\/10.1126\/science.1198687.","journal-title":"Science"},{"issue":"7","key":"2990_CR202","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","volume":"11","author":"HG Ljunggren","year":"1990","unstructured":"Ljunggren HG, K\u00e4rre K. In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237\u201344. 10.1016\/0167\u20135699(90)90097-s.","journal-title":"Immunol Today"},{"issue":"6055","key":"2990_CR203","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","volume":"319","author":"K K\u00e4rre","year":"1986","unstructured":"K\u00e4rre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675\u20138. https:\/\/doi.org\/10.1038\/319675a0.","journal-title":"Nature"},{"issue":"12","key":"2990_CR204","doi-asserted-by":"publisher","first-page":"e1250992","DOI":"10.1080\/2162402x.2016.1250992","volume":"5","author":"XY Zhao","year":"2016","unstructured":"Zhao XY, Zhao XS, Wang YT, Chen YH, Xu LP, Zhang XH, et al. Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. Oncoimmunology. 2016;5(12):e1250992. https:\/\/doi.org\/10.1080\/2162402x.2016.1250992.","journal-title":"Oncoimmunology"},{"issue":"8","key":"2990_CR205","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.bbmt.2017.04.029","volume":"23","author":"GB McDonald","year":"2017","unstructured":"McDonald GB, Tabellini L, Storer BE, Martin PJ, Lawler RL, Rosinski SL, et al. Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. Biol Blood Marrow Transpl. 2017;23(8):1257\u201363. https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.029.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"2990_CR206","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","volume":"125","author":"DK Reichenbach","year":"2015","unstructured":"Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q, et al. The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015;125(20):3183\u201392. https:\/\/doi.org\/10.1182\/blood-2014-10-606830.","journal-title":"Blood"},{"issue":"308","key":"2990_CR207","doi-asserted-by":"publisher","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","volume":"7","author":"J Zhang","year":"2015","unstructured":"Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015;7(308):308ra160. https:\/\/doi.org\/10.1126\/scitranslmed.aab0166.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2990_CR208","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.trre.2025.100962","volume":"39","author":"Q Wu","year":"2025","unstructured":"Wu Q, Yuan Y, Yang H, Fu Q. Harnessing the TNF-TNFR pathway for graft tolerance: Selective immunomodulation in islet transplantation. Transpl Rev (Orlando). 2025;39(4):100962. https:\/\/doi.org\/10.1016\/j.trre.2025.100962.","journal-title":"Transpl Rev (Orlando)"},{"key":"2990_CR209","doi-asserted-by":"publisher","first-page":"963689722114944","DOI":"10.1177\/09636897221149444","volume":"32","author":"L Cao","year":"2023","unstructured":"Cao L, Ma X, Zhang J, Yang M, He Z, Yang C, et al. CD27-Expressing Xenoantigen-Expanded Human Regulatory T Cells Are Efficient in Suppressing Xenogeneic Immune Response. Cell Transpl. 2023;32:9636897221149444. https:\/\/doi.org\/10.1177\/09636897221149444.","journal-title":"Cell Transpl"},{"issue":"6","key":"2990_CR210","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/bloodadvances.2021005770","volume":"6","author":"CM Rowan","year":"2022","unstructured":"Rowan CM, Smith L, Sharron MP, Loftis L, Kudchadkar S, Duncan CN, et al. A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation. Blood Adv. 2022;6(6):1866\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2021005770.","journal-title":"Blood Adv"},{"key":"2990_CR211","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1399-0012.2009.01103.x","volume":"23","author":"E Fritzsching","year":"2009","unstructured":"Fritzsching E, Kunz P, Maurer B, P\u00f6schl J, Fritzsching B. Regulatory T cells and tolerance induction. Clin Transpl. 2009;23:10\u20134. https:\/\/doi.org\/10.1111\/j.1399-0012.2009.01103.x.","journal-title":"Clin Transpl"},{"issue":"4","key":"2990_CR212","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/leu.2014.310","volume":"29","author":"Y Liu","year":"2015","unstructured":"Liu Y, Wu Y, Wang Y, Cai Y, Hu B, Bao G, et al. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia. 2015;29(4):939\u201346. https:\/\/doi.org\/10.1038\/leu.2014.310.","journal-title":"Leukemia"},{"issue":"13","key":"2990_CR213","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood.2023022735","volume":"144","author":"JA Pidala","year":"2024","unstructured":"Pidala JA, Gooley TA, Luznik L, Blazar BR. Chronic graft-versus-host disease: unresolved complication or ancient history? Blood. 2024;144(13):1363\u201373. https:\/\/doi.org\/10.1182\/blood.2023022735.","journal-title":"Blood"},{"issue":"3","key":"2990_CR214","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/clim.2001.5240","volume":"104","author":"A Kokalj","year":"2002","unstructured":"Kokalj A, Greinix HT, Ciovica M, Kittler H, Kalhs P, Knobler RM, et al. Effects of extracorporeal photoimmunotherapy on soluble IL-2Ralpha, TNF-RI, and CD8 in patients with steroid-resistant acute graft-versus-host disease. Clin Immunol. 2002;104(3):248\u201355. https:\/\/doi.org\/10.1006\/clim.2001.5240.","journal-title":"Clin Immunol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02990-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:59:05Z","timestamp":1781769545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02990-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":214,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2990"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02990-1","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}